We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Metagenomics Analysis Tool Reduces False Discovery Rates

By LabMedica International staff writers
Posted on 30 Mar 2015
Print article
Image: Many molecular biology studies begin with purified DNA and RNA extracted from complex environments such as the human gut (Photo courtesy of Los Alamos [US] National Laboratory).
Image: Many molecular biology studies begin with purified DNA and RNA extracted from complex environments such as the human gut (Photo courtesy of Los Alamos [US] National Laboratory).
Genomic researchers recently described a novel new tool for analyzing the complex data generated during DNA screens of mixed populations of organisms such as the human gut microbiome.

DNA screening of entire communities of organisms has been termed metagenomics. Such screening generates an enormous data set of short sequences, or "reads," which must be evaluated in order to yield meaningful information. While existing microbial community profiling methods have attempted to rapidly classify the millions of reads output from modern DNA sequencing platforms, the combination of incomplete databases, similarity among otherwise divergent genomes, errors and biases in sequencing technologies, and the large volumes of sequencing data required for metagenome sequencing has led to unacceptably high false discovery rates (FDR).

To correct these problems, investigators at the Los Alamos National Laboratory (New Mexico, USA) developed a new method for analysis of DNA sequencing data. The new tool, described in the March 12, 2015, online edition of the journal Nucleic Acids Research, is called Genomic Origins through Taxonomic CHAllenge or GOTTCHA, which makes use of a database of reference genomes that have been preprocessed to retain only unique segments of the genomes at any level of taxonomy.

GOTTCHA analyzes the distribution and depth of coverage of only the unique fraction of each reference genome—the unique genome—to identify the true community composition and accurate relative abundance of members of the community. GOTTCHA uses empirically-derived coverage limits, supported by machine-learning approaches, to set the limits of detection. The result is a scalable, all-purpose, metagenomic community profiler with superior classification and statistical performance over all currently available tools.

"We have developed a new tool in this rapidly expanding and evolving field of what is called metagenomics," said senior author Dr. Patrick Chain, metagenomics team leader at the Los Alamos National Laboratory. "It uses nucleic acid data and looks for sections that map uniquely to a preconstructed database."

"Metagenomics is the study of entire microbial communities using genomics, such as when you sequence the DNA of a whole community of organisms at once," said Dr. Chain. "The result is an enormous data set of short sequences, or reads, that you need to sort through to try to understand which organisms are actually present, and what they may be doing. Here at Los Alamos, we specialize in incredibly large data sets; we know how to handle them whether it is for physics, ocean, or climate modeling, or for complex biological insights."

The GOTTCHA software, associated databases, and training datasets are accessible to biotech researchers online (please see Related Links below).

Related Links:
Los Alamos [US] National Laboratory
GOTTCHA


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
High Performance Centrifuge
CO336/336R

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.